Canadian International Pharma Corp. focuses on the manufacture and distribution pharmaceutical and nutraceutical drugs. More Details
Worrying balance sheet with weak fundamentals.
Share Price & News
How has Canadian International Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CIP.H's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: CIP.H exceeded the Canadian Pharmaceuticals industry which returned -23.2% over the past year.
Return vs Market: CIP.H exceeded the Canadian Market which returned -3.6% over the past year.
Price Volatility Vs. Market
How volatile is Canadian International Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 months ago | Simply Wall StWe Think Canadian International Pharma (CVE:CIP.H) Needs To Drive Business Growth Carefully
9 months ago | Simply Wall StDo Directors Own Canadian International Pharma Corp. (CVE:CIP.H) Shares?
Is Canadian International Pharma undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Canadian International Pharma is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Canadian International Pharma has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
- Take a look at our analysis of CIP.H's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Canadian International Pharma regulatory filings.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
How is Canadian International Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Canadian International Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of CIP.H’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Canadian International Pharma competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Canadian International Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CIP.H is currently unprofitable.
Growing Profit Margin: CIP.H is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CIP.H is unprofitable, but has reduced losses over the past 5 years at a rate of 42.4% per year.
Accelerating Growth: Unable to compare CIP.H's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CIP.H is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (30.9%).
Return on Equity
High ROE: CIP.H's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Canadian International Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: CIP.H has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: CIP.H has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: CIP.H has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: CIP.H's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CIP.H has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: Insufficient data to determine if CIP.H has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Canadian International Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CIP.H's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CIP.H's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CIP.H's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CIP.H's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CIP.H's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Doug Mason (72 yo)
Mr. Douglas L. Mason, also known as Doug, has been Member of Independent Advisory Board at BevCanna Enterprises Inc. since July 20, 2020. Mr. Mason serves as an Independent Director at TransCanna Holdings ...
CEO Compensation Analysis
Compensation vs Market: Doug's total compensation ($USD0.00) is below average for companies of similar size in the Canadian market ($USD170.66K).
Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.
|Chairman & CEO||6.25yrs||no data||0.00087% |
|CFO & Director||8.33yrs||no data||no data|
|Director||0.083yr||no data||no data|
|Chair of the Advisory||no data||no data||no data|
|Member of Advisory Board||no data||no data||no data|
Experienced Board: CIP.H's board of directors are considered experienced (8.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Canadian International Pharma Corp.'s company bio, employee growth, exchange listings and data sources
- Name: Canadian International Pharma Corp.
- Ticker: CIP.H
- Exchange: TSXV
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$576.795k
- Shares outstanding: 38.45m
- Website: https://www.canpharmacorp.ca
- Canadian International Pharma Corp.
- 2489 Bellevue Avenue
- West Vancouver
- British Columbia
- V7V 1E1
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CIP.H||TSXV (TSX Venture Exchange)||Yes||Common Shares||CA||CAD||Jan 1990|
|BPCO.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Jan 1990|
Canadian International Pharma Corp. focuses on the manufacture and distribution pharmaceutical and nutraceutical drugs. The company was formerly known as Black Panther Mining Corp. and changed its name to ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/18 23:44|
|End of Day Share Price||2020/10/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.